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Abstract
Background: The production of gamma-amino butyric acid (GABA) is dependent on glutamate decarboxylases
(GAD65 and GAD67), the enzymes that catalyze the decarboxylation of glutamate to GABA. Based on studies
suggesting a role of the airway epithelial GABAergic system in asthma-related mucus overproduction, we
hypothesized that cigarette smoking, another disorder associated with increased mucus production, may modulate
GABAergic system-related gene expression levels in the airway epithelium.
Methods: We assessed expression of the GABAergic system in human airway epithelium obtained using
bronchoscopy to sample the epithelium and microarrays to evaluate gene expression. RT-PCR was used to confirm
gene expression of GABAergic system gene in large and small airway epithelium from heathy nonsmokers and
healthy smokers. The differences in the GABAergic system gene was further confirmed by TaqMan,
immunohistochemistry and Western analysis.
Results: The data demonstrate there is a complete GABAergic system expressed in the large and small human
airway epithelium, including glutamate decarboxylase, GABA receptors, transporters and catabolism enzymes.
Interestingly, of the entire GABAergic system, smoking modified only the expression of GAD67, with marked up-
regulation of GAD67 gene expression in both large (4.1-fold increase, p < 0.01) and small airway epithelium of
healthy smokers (6.3-fold increase, p < 0.01). At the protein level, Western analysis confirmed the increased
expression of GAD67 in airway epithelium of healthy smokers compared to healthy nonsmokers (p < 0.05). There
was a significant positive correlation between GAD67 and MUC5AC gene expression in both large and small airway
epithelium (p < 0.01), implying a link between GAD67 and mucin overproduction in association with smoking.
Conclusions: In the context that GAD67 is the rate limiting enzyme in GABA synthesis, the correlation of GAD67
gene expression with MUC5AC expressions suggests that the up-regulation of airway epithelium expression of
GAD67 may contribute to the increase in mucus production observed in association with cigarette smoking.
Trial registration: NCT00224198; NCT00224185
Background
Gamma-aminobutyric acid (GABA) is a multifunctional
mediator that functions as a neurotransmitter in the
central nervous system and a trophic factor during ner-
vous system development, affecting proliferation, differ-
entiation and cell death [1-3]. GABA is synthesized
from glutamate, and catalyzed by GAD65 and GAD67,
glutamic acid decarboxylase [1-3]. In the CNS, transpor-
ters, receptors and catabolic enzymes work in a coordi-
nated fashion to control the availability of GABA [1-3].
It is now recognized that GABA also functions in a
variety of organs outside of the CNS [1,3,4]. In the lung,
a series of recent studies suggest that the GABAergic
signaling system plays a role in the control of asthma-
related airway constriction and mucin secretion [5-9].
In the context that goblet cell hyperplasia and mucin
overproduction is also associated with cigarette smoking
[10-12], we hypothesized that components of the
GABAergic system may also be altered in the airway
epithelium of cigarette smokers. To assess this hypoth-
esis, we examined our microarray database of large and
small airway gene expression of healthy nonsmokers and
healthy smokers to determine if the GABAergic system
was expressed. This was verified by PCR analysis.
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The data demonstrate there is expression of genes for a
complete GABAergic system in the airway epithelium.
Interestingly, the expression of GAD67 was markedly
modified by smoking, with increased expression in
healthy smokers compared to healthy nonsmokers at the
mRNA and protein levels. In the context that mucus
overproduction is commonly associated with cigarette
smoking, GAD67 may be a pharmacologic target for the
treatment of smoking-related disorders.
Methods
Study Population
Healthy nonsmokers and healthy smokers were
recruited using local print media. The study population
was evaluated at the Department of Genetic Medicine
Clinical Research Facility under the auspices of the
Weill Cornell NIH Clinical and Translational Science
Center with approval by the Weill Cornell Medical Col-
lege Institutional Review Board. Written informed con-
sent was obtained from each volunteer before
enrollment in the study. Individuals were determined to
be phenotypically normal on the basis of clinical history
and physical examination, routine blood screening tests,
urinalysis, chest X-ray, ECG and pulmonary function
testing. Current smoking status was confirmed by his-
tory, venous carboxyhemoglobin levels and urinalysis for
levels of nicotine and its derivative cotinine. All indivi-
duals were asked not to smoke for at least 12 hr prior
to bronchoscopy.
Collection of Airway Epithelial Cells
Epithelial cells from the large and small airways were col-
lected using flexible bronchoscopy. After achieving mild
sedation and anesthesia of the vocal cords, a flexible
bronchoscope (Pentax, EB-1530T3) was advanced to the
desired bronchus. Large airway epithelial samples were
collected by gentle brushing of the 3rd to 4th order
bronchi and small airway samples were collected from
10th to 12th order bronchi using methods previously
described [13]. The large and small airway epithelial cells
were subsequently collected separately in 5 ml of LHC8
medium (GIBO, Grand Island, NY). An aliquot of this
was used for cytology and differential cell count and the
remainder was processed immediately for RNA extrac-
tion. Total cell counts were obtained using a hemocyt-
ometer, whereas differential cell counts were determined
on sedimented cells prepared by centrifugation (Cytospin
11, Shandon Instruments, Pittsburgh, PA) and stained
with DiffQuik (Baxter Healthcare, Miami, FL).
RNA Extraction and Microarray Processing
The HG-U133 Plus 2.0 microarray (Affymetrix, Santa
Clara, CA), which includes probes for more than 47,000
transcripts genome-wide, was used to evaluate gene
expression. Total RNA was extracted using a modified
version of the TRIzol method (Invitrogen, Carlsbad,
CA), in which RNA is purified directly from the aqueous
phase (RNeasy MinElute RNA purification kit, Qiagen,
Valencia, CA). RNA samples were stored in RNA Secure
(Ambion, Austin, TX) at -80°C. RNA integrity was
determined by running an aliquot of each RNA sample
on an Agilent Bioanalyzer (Agilent Technologies, Palo
Alto, CA). The concentration was determined using a
NanoDrop ND-1000 spectrophotometer (NanoDrop
Technologies, Wilmington, DE). Double-stranded cDNA
was synthesized from 1 to 2 μg total RNA using the
GeneChip One-Cycle cDNA Synthesis Kit, followed by
cleanup with GeneChip Sample Cleanup Module,
in vitro transcription (IVT) reaction using the GeneChip
IVT Labeling Kit, and cleanup and quantification of the
biotin-labeled cDNA yield by spectrophotometry. All
kits were from Affymetrix (Santa Clara, CA). All HG-
U133 Plus 2.0 microarrays were processed according to
Affymetrix protocols, hardware and software, including
being processed by the Affymetrix fluidics station 450
and hybridization oven 640, and scanned with an Affy-
metrix Gene Array Scanner 3000 7G. Overall microarray
quality was verified by the following criteria: (1) RNA
Integrity Number (RIN) ≥7.0; (2) 3’/5’ ratio for GAPDH
≤3; and (3) scaling factor ≤10.0.
Microarray Data Analysis
Captured images were analyzed using Microarray Suite
version 5.0 (MAS 5.0) algorithm (Affymetrix) as pre-
viously described [13-15]. The data were normalized
using GeneSpring version 7.0 software (Agilent Technol-
ogies, Palo Alto, CA) as follows: (1) per array, by divid-
ing raw data by the 50th percentile of all measurements;
and (2) per gene, by dividing the raw data by the med-
ian expression level for all the genes across all arrays in
a dataset.
RT-PCR
To confirm the expression of the genes in the GABAer-
gic system, total RNA from large airway epithelium and
small airway epithelium was prepared as described
above. Total RNA from whole human brain (Clontech,
Mountain View, CA) was used as a positive control.
RNA was reverse transcribed by TaqMan Reverse Tran-
scription Regents (ABI, Foster City, CA). Routine PCR
was performed using Platinum PCR Supermix (Invitro-
gen, Carlsbad, CA) at indicated temperatures and times
(Additional file 1, Table S1).
TaqMan RT-PCR Confirmation of Microarray Expression
Levels
To quantify relative mRNA levels of GAD67, TaqMan
real-time RT-PCR was performed on a random sample
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of large and small airway samples of 10 healthy non-
smokers and 12 healthy smokers that had been used for
the HG-U133 Plus 2.0 microarray analyses. First, cDNA
was synthesized from 2 μg RNA in a 100 μl reaction
volume, using the Reverse Transcriptase Reaction Kit
(Applied Biosystems), with random hexamers as pri-
mers. Dilutions of 1:10 and 1:100 were made from each
sample and triplicate wells were run for each dilution.
TaqMan PCR reactions were carried out using pre-
made kits from Applied Biosystems and 2 μl of cDNA
was used in each 25 μl reaction volume. b-actin was
used as the endogenous control, and relative expression
levels were determined using the ΔΔCt method (Applied
Biosystems). The b-actin probe was labeled with VIC
and the probe for GAD67 with FAM. The PCR reac-
tions were run in an Applied Biosystems Sequence
Detection System 7500.
Localization of GAD67 Expression in Human Airway
Epithelium
To determine the airway epithelial localization of
GAD67 expression, bronchial biopsies were obtained by
flexible bronchoscopy from the large airway epithelium
of 10 healthy nonsmokers and 10 healthy smokers [13].
Immunohistochemistry was carried out on these paraf-
fin-embedded endobronchial biopsies. Sections were
deparaffinized and rehydrated through a series of
xylenes and alcohol. To enhance staining, an antigen
retrieval step was carried out by boiling the sections at
100°C, 20 min in citrate buffer solution (Labvision, Fre-
mont, CA), followed by cooling at 23°C, 20 min. Endo-
genous peroxidase activity was quenched using 0.3%
H2O2, and blocking was performed with normal goat
serum to reduce background staining. Samples were
incubated with the mouse monoclonal anti-GAD67 anti-
body (1 μg/μl at 1/25 dilution, Millipore, Billerica, MA),
16 hr, 4°C. Cytospin slides of 293 cells transfected with
pcDNA3.1-GAD67, and pcDNA3.1 plasmids were used
as controls. Vectastain Elite ABC kit (Vector Labora-
tories, Burlingame, CA) and 3-amino-9-ethylcarbazole
(AEC) substrate kit (Dako, Carpinteria, CA) were used
to detect antibody binding, and the sections were coun-
terstained with hematoxylin (Sigma-Aldrich, St. Louis,
MO), and mounted using GVA mounting medium
(Zymed, San Francisco, CA). Brightfield microscopy was
performed using a Nikon Microphot microscope and
images were captured with an Olympus DP70 CCD
camera.
Western Analysis
Western analysis was used to quantitatively assess
GAD67 protein expression in small airway epithelium
from healthy nonsmokers and healthy smokers. Brushed
small airway epithelial cells were obtained as described
above. Initially, the cells were centrifuged at 600 g,
5 min, 4°C. The whole cells were lysed with red cell
lysis buffer (Sigma-Aldrich), followed by whole cell lysis
buffer (ACK lysing buffer, Invitrogen), and then protease
inhibitor (Cell Lytic Mammalian Tissue Lysis/Extraction
reagent, Sigma-Aldrich) was added to the sample. The
sample was centrifuged at 10,000 g and the protein-
containing supernatant was collected. The protein con-
centrations were assessed using a bicinchoninic acid
(BCA) protein concentration kit (Pierce, Rockford, IL).
Equal concentration of protein (20 μg), mixed with SDS
Sample Loading Buffer (Bio-Rad, Hercules, CA) and
reducing agent, was loaded on Tris-glycine gels (Bio-
Rad). Protein electrophoresis was carried out at 100 V,
2 hr, 23°C. Sample proteins were transferred (25 V, 1
hr, 4°C) to a 0.45 μm PVDF membrane (Invitrogen)
using Tris-glycine transfer buffer (Bio-Rad). After trans-
fer the membranes were blocked with 5% milk in PBS
for 1 hr, 23°C. The membranes were incubated with
primary mouse monoclonal anti-GAD67 antibody (Milli-
pore, Billerica, MA) at 1:2000 dilution, 2 hr, 4°C. Protein
extracted from pcDNA 3.1-GAD67 transfected 293 cells
was used as a positive control. Detection was performed
using horseradish peroxidase-conjugated anti-mouse
antibody (1:10,000 dilution, Santa Cruz Biotechnology,
Santa Cruz, CA) and the Enhanced Chemiluminescent
reagent (ECL) system (GE, Healthcare, Pittsburgh, PA)
using Hyperfilm ECL (GE Healthcare). The membrane
was subsequently stripped and reincubated with horse-
radish peroxidase-conjugated anti-b-actin antibody
(Santa Cruz Biotechnology) as a control for equal pro-
tein concentration. To assess the Western analyses
quantitatively, the film was digitally imaged, maintaining
exposure within the linear range of detection. The con-
trast was inverted, the pixel intensity of each band
determined, and the background pixel intensity for a
negative area of the film of identical size subtracted
using MetaMorph image analysis software (Universal
Imaging, Downingtown, PA).
MUC5AC Staining
For MUC5AC staining in large airway and small airway
epithelium, brush cells cytospin slides were stained with
mouse anti-human MUC5AC antibody (Vector, Burlin-
game, CA) and detected by Cy3 labeled goat anti-mouse
antibody (Jackson, West Grove, PA). Nuclei were coun-
terstained with DAPI (Invitrogen, Carlsbad, CA). Based
on the microarray data, we defined “high GAD67” or
“high MUC5AC” gene expression as ≥median + 1 stan-
dard deviation and low GAD67 or low MUC5AC gene
expression as ≤median - 1 standard deviation. Based on
this criteria, 3 healthy smokers with high GAD67 and
high MUC5AC gene expression and 3 healthy smokers
with low GAD67 and low MUC5AC gene expression
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were assessed for MUC5AC protein expression by
immunofluorescence staining.
Statistical Analysis
HG-U133 Plus 2.0 microarrays were analyzed using
GeneSpring software. Average expression values for
GAD67 in large and small airway samples (HG-U133
Plus 2.0) were calculated from normalized expression
levels for nonsmokers and healthy smokers. Statistical
comparisons for microarray data were calculated using
GeneSpring software and associated two-tailed Students
t-test. Benjamini-Hochberg correction was applied to
limit the false discovery rate. Statistical comparisons for
categorical data were achieved using Chi-squared test.
Correlations were performed using Pearson correlation.
All other statistical comparisons were calculated using a
two-tailed (Welsh) t-test.
Web Deposition of Data
All data has been deposited in the Gene Expression
Omnibus (GEO) site (http://www.ncbi.nlm.nih.gov/geo),
curated by the National Center for Bioinformatics.
Accession number for the data is GSE17905.
Results
Study Population
Large airway samples from 21 healthy nonsmokers and
31 healthy smokers and small airway samples from a
total of 105 individuals, including 47 healthy nonsmo-
kers and 58 healthy smokers, were analyzed with Affy-
metrix HG-U133 Plus 2.0 microarray (Table 1). All
healthy individuals had no significant prior medical his-
tory, no history suggestive of asthma and a normal gen-
eral physical examination. There were no differences
between groups with regard to ancestral background (p
> 0.05). For the large airways and small airway, there
were no gender difference (p > 0.5), and no age differ-
ence (p > 0.1), between the nonsmoker and smoker
groups. All individuals were HIV negative, with blood
and urine parameters within normal ranges (p > 0.05 for
all comparisons). Urine nicotine and cotinine, and
venous blood carboxyhemoglobin levels of smokers con-
firmed current smoking status of these individuals. Pul-
monary function testing, with and without
bronchodilators, revealed normal lung function in
healthy nonsmokers and all healthy smokers (Table 1).
Sampling of Airway Epithelium
Airway epithelial cells were obtained by fiberoptic
bronchoscopy and brushing of the large (3rd to 4th
order) and small (10th to 12th order) airways. The num-
ber of cells recovered ranged from 6.3 to 7.2 × 106
(Table 1). The percent epithelial cells recovered was, on
average, 99% in all groups. The various categories of
airway epithelial cells were, as expected, from the large
and small airways [13,15].
Expression of GABAergic System-related Genes in the
Airway Epithelium
Based on the function in GABAergic system, we cate-
gorized GABAergic system-related genes into 4 groups:
synthesis, receptor, transport, metabolism (Figure 1,
Table 2). Synthesis-related genes include GAD65 and
GAD67; receptor-related genes include 19 GABA-A
receptor subunits (alpha 1-6, beta 1-3, epsilon, gamma
1-3, pi, theta, delta, rho1-3) and 2 GABA-B receptor
subunits (GABBR1, GABBR2). Transport-related genes
include GABA vesicular transporter (VGAT), GABA
transporter 1 (GAT-1), GAT-2, GAT-3, Na(+)/Cl(-)
betaine/GABA transporter (BGT-1). Metabolism-related
genes include GABA transferase (GABA-T) and alde-
hyde dehydrogenase 5 family, member A1 (ALDH5A1).
Of the 30 GABAergic system-related genes surveyed
using the Affymetrix HG-U133 Plus 2.0 array and the
criteria of Affymetrix Detection Call of Present (P call)
in ≥20%, there were 13 GABAergic system genes
expressed in the large airway epithelium of healthy non-
smokers and 11 in the large airway epithelium of
healthy smokers (Figure 2A, B). The 13 GABAergic
genes expressed in the large airway epithelium of non-
smokers included synthesis-related genes GAD67; recep-
tors GABRB2, GABRB3, GABRE, GABRP, GABRR2,
GABBR1, GABBR2; transport-related genes GAT-1,
GAT-2, BGT-1 and metabolism-related genes GABA-T,
ALDH5A1. The 11 GABAergic gene expressed in the
large airway epithelium of smokers included synthesis-
related genes GAD67; receptors GABRB2, GABRB3,
GABRE, GABRG1, GABRP, GABBR1; transport-related
genes GAT-1,GAT-2 and metabolism-related genes
GABA-T, ALDH5A1. In the small airway epithelium
there were 13 GABAergic genes expressed in healthy
nonsmokers and 12 GABAergic genes in healthy smo-
kers, respectively (Figure 2A, B). The 13 GABAergic
genes expressed in the small airway epithelium of non-
smokers included synthesis-related genes GAD67; recep-
tors GABRB2, GABRB3, GABRG1, GABRG3, GABRE,
GABRP, GABRR2, GABBR1; transport-related genes
GAT-1,GAT-2 and metabolism-related genes GABA-T,
ALDH5A1. The 12 GABAergic gene expressed in the
small airway epithelium of smokers included synthesis-
related genes GAD67; receptors GABRB2, GABRB3,
GABRE, GABRG1, GABRP, GABRR2, GABBR1; trans-
port-related genes GAT-1,GAT-2 and metabolism-
related genes GABA-T, ALDH5A1.
Independent of smoking status, the only GABA synth-
esis enzymes expressed in the large airway epithelium
and small airway epithelium was GAD67. In regard to
transporters, there was no GAT-3 and VGAT
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expression in human large and small airway epithelium.
For the GABA metabolism-related genes, both GABAT
and ALDH5A1 were expressed in the large and small
airway epithelium. In summary, each functional group
of the GABA system has genes expressed in airway
epithelium, forming a complete GABAergic system. RT-
PCR confirmed that a complete GABAergic system was
expressed in the airway epithelium (Figure 2C).
Up-regulation of GAD67 in Large and Small Airway
Epithelium of Healthy Smokers
Of all of the GABAergic system genes expressed in the
large and small airways, only GAD67 was significantly
changed >2-fold in healthy smokers compared to
healthy nonsmokers (Figure 3A, B). As assessed using
the microarrays, GAD67 was significantly up-regulated
in healthy smokers compared to healthy nonsmokers in
the large airway epithelium (4.1-fold increase, p < 0.01;
Figure 4A), and healthy smokers compared to healthy
nonsmokers in the small airway epithelium (6.3-fold
increase, p < 0.01; Figure 4B). To confirm the results
obtained from the microarray screen, TaqMan RT-PCR
was carried out on RNA samples from the large and
small airways epithelium of 10 healthy nonsmokers and
12 healthy smokers, respectively. The TaqMan data con-
firmed that GAD67 was significantly up-regulated in the
large airways of healthy smokers (8.8-fold increase, p <
0.01) compared to healthy nonsmokers (Figure 4C), and
in the small airways of healthy smokers (3.8-fold
increase, p < 0.01) compared to healthy nonsmokers
(Figure 4D). Interestingly, when human airway epithelial
cell line 16HBE was treated with cigarette smoking
extract in vitro, GAD67 gene expression was also up-
regulated (not shown).
Immunohistochemical Assessment of GAD67 Expression
The GAD67 expression was assessed at the protein level
with immunohistochemistry evaluation of endobronchial
biopsy specimens from the large airways of healthy non-
smokers and healthy smokers. The specificity of the
anti-GAD67 monoclonal antibody was assessed in 293
cells transfected with the human GAD67 cDNA. Only
GAD67 transfected cells were GAD67 positive, while
control plasmids transfected cells were GAD67 negative
Table 1 Study Population of Airway Epithelial Samples 1
Large airways Small airways
Parameter Healthy nonsmokers Healthy smokers Healthy nonsmokers Healthy smokers
n 21 31 47 58
Sex (male/female) 15/6 21/10 33/14 38/20
Age (yr) 41 ± 8 44 ± 7 42 ± 11 43 ± 7
Race (B/W/O)2 10/7/4 20/7/4 23/18/6 35/14/9
Smoking history (pack-yr) 0 28 ±18 0 28 ± 17
Urine nicotine (ng/ml) Negative 746 ± 904 Negative 1298 ±1692
Urine cotinine (ng/ml) Negative 973 ± 690 Negative 1246 ± 974
Venous CO-Hb3 0.64 ± 0.93 2.0 ±1.9 0.4 ± 0.8 1.8 ± 1.9
Pulmonary function4
FVC 106 ± 13 110 ± 11 107 ± 14 109 ± 13
FEV1 107 ± 17 110 ± 12 106 ± 15 107 ± 14
FEV1/FVC 82 ± 5 81 ± 5 82 ± 6 80 ± 5
TLC 100 ± 14 103 ± 11 101 ±13 100 ±12
DLCO 101 ± 16 95 ± 11 99 ± 15 94 ± 11
Epithelial cells
Total number × 106 7.0 ± 3 7.0 ± 3.3 6.3 ± 2.9 7.2 ± 3.0
% epithelial 99.7 ± 0.6 99.8 ± 0.5 99.3 ± 1.1 99.1 ± 1.3
% inflammatory 0.3 ± 0.6 0.2 ± 0.5 0.7 ± 1.1 0.8 ± 1.3
Differential cell count (%)
Ciliated 53.6 ± 6.6 47.8 ± 13.7 74.3 ± 7.4 65.7 ± 12.5
Secretory 10 ± 4.4 10 ± 4.1 6.6 ± 3.5 9.1 ± 4.5
Basal 22.4 ± 3.4 25.9 ± 9.9 11.1 ± 5.3 12.7 ± 6.7
Undifferentiated 14.1 ± 5.2 16.5 ± 8.9 7.3 ± 3.2 11.8 ± 6.7
1Data are presented as mean ∀ standard deviation.
2B = Black, W = White, O = Other.
3Venous carboxyhemoglobin, a secondary marker of current smoking; nonsmokers, normal value <1.5%.
4Pulmonary function testing parameters are given as % of predicted value with the exception of FEV1/FVC, which is reported as % observed; FVC - forced vital
capacity, FEV1 - forced expiratory volume in 1 sec, TLC - total lung capacity, DLCO - diffusing capacity.
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(not shown). In the airway epithelium, positive staining
for GAD67 was mainly observed in the basal cell popu-
lation, but also in ciliated cells (Figure 5). Consistent
with our microarray data, there was a variability of
GAD67 staining in smokers, with expression ranging
from similar to that of healthy nonsmokers (compared
panel C to A) to intense GAD67 expression (panels G,
I). However, there was much more GAD67 staining
overall in the airways epithelium of healthy smokers
compared to healthy nonsmokers. Interestingly, squa-
mous metaplasia also showed strong GAD67 staining
(panel K).
Western Analysis of GAD67 Protein Expression
Western analysis carried out on small airway epithelial
samples from healthy nonsmokers and healthy smokers
was used to quantitatively assess GAD67 protein expres-
sion. This analysis confirmed the increased GAD67 pro-
tein expression in healthy smokers compared to healthy
nonsmokers (p < 0.05, Figure 6).
Association Between GAD67 and MUC5AC Gene
Expression in Smokers
It has been suggested that GABA can stimulate mucin
production in cultured airway epithelial cells [7]. To
investigate the relationship between GAD67 and
MUC5AC gene expression (the dominant smoking-
responsive mucin gene in the human airway epithelium
[11,12,16]), the normalized expression of GAD67 was
compared to MUC5AC expression. By this method,
known mucus biosynthesis-associated genes [e.g., SPDEF
(SAM pointed domain containing ets transcription fac-
tor)] were found to be highly correlated with MUC5AC
gene expression. Significant positive correlations were
observed for GAD67 with MUC5AC gene expression in
both large (r = 0.46, p < 0.01, Figure 7A) and small air-
way epithelium (r = 0.47, p < 0.01, Figure 7B). To
further assess this association, MUC5AC protein expres-
sion was examined in airway brushed cells from healthy
smokers with high GAD67 and high MUC5AC gene
expression or with low GAD67 and low MUC5AC
expression based on microarray data. Immunofluores-
cence microscopy demonstrated stronger and more
extensive distribution of MUC5AC staining in subjects
with high GAD67 and high MUC5AC gene expression
(Figure 7C, large airway; Figure 7D, small airway) com-
pared to subjects with low GAD67 and low MUC5AC
gene expression (Figure 7E, large airway; Figure 7F,
small airway). Consistent with this observation, Western
analysis showed increased GAD67 expression in small
airway epithelium of healthy smokers and COPD smo-
kers compared to nonsmokers (Additional file 1, Figure
Figure 1 Schematic illustration of GABAergic system. GABA is synthesized from glutamate by the glutamic acid decarboxylases GAD67 and
GAD65. GABA is released by either a vesicle-mediated process, a vesicular neurotransmitter transporter (VGAT) or a nonvesicular process by
reverse transport. GABA exerts its physiological effects through GABA-A and GABA-B receptors. The GABAergic signal is terminated by rapid
uptake of GABA by specific high affinity GABA transporters (GATs). There are 4 distinct genes encoding GABA membrane transporters, GAT-1,
GAT-2, GAT-3 and BGT-1. GABA is metabolized by GABA transaminase (GABA-T) and succinic semialdehyde dehydrogenase (ALDH5A1).
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Table 2 Expression of GABAergic System Genes in Large Airway and Small Airway Epithelium of Healthy Smokers




















206780_at GAD65 glutamate decarboxylase 2 1.08 0.86 0.0 1.05 0.89 0.0
205278_at GAD67 glutamate decarboxylase 1 4.09 2.07 ×
10-5




244118_at GABRA1 gamma-aminobutyric acid (GABA) A receptor, alpha 1 -1.27 0.60 1.9 1.12 0.84 1.9
207014_at GABRA2 gamma-aminobutyric acid (GABA) A receptor, alpha 2 -1.26 0.60 0.00 1.12 0.83 1.0
207210_at GABRA3 gamma-aminobutyric acid (GABA) A receptor, alpha 3 1.80 0.16 0.00 1.17 0.69 1.0
208463_at GABRA4 gamma-aminobutyric acid (GABA) A receptor, alpha 4 1.21 0.63 7.7 1.05 0.89 6.7
215531_s_at GABRA5 gamma-aminobutyric acid (GABA) A receptor, alpha 5 -1.46 0.46 1.9 1.01 0.95 1.0
207182_at GABRA6 gamma-aminobutyric acid (GABA) A receptor, alpha 6 1.07 0.91 0.0 1.49 0.20 0.0
207010_at GABRB1 gamma-aminobutyric acid (GABA) A receptor, beta 1 1.38 0.57 9.6 -1.14 0.81 6.7
242344_at GABRB2 gamma-aminobutyric acid (GABA) A receptor, beta 2 1.34 0.33 61.5 1.15 0.70 41.9
229724_at GABRB3 gamma-aminobutyric acid (GABA) A receptor, beta 3 -1.01 0.98 96.2 1.10 0.81 97.1
241805_at GABRG1 gamma-aminobutyric acid (GABA) A receptor, gamma 1 1.09 0.86 15.4 -1.11 0.82 33.3
1568612_at GABRG2 gamma-aminobutyric acid (GABA) A receptor, gamma 2 1.02 0.96 0.0 1.34 0.49 0.0
216895_at GABRG3 gamma-aminobutyric acid (GABA) A receptor, gamma 3 -1.10 0.86 9.6 -1.74 0.14 14.3
204537_s_at GABRE gamma-aminobutyric acid (GABA) A receptor, epsilon 1.13 0.56 98.1 -1.29 0.12 72.4
220886_at GABRQ gamma-aminobutyric acid (GABA) receptor, theta 1.34 0.56 1.9 -1.03 0.91 1.0
230255_at GABRD gamma-aminobutyric acid (GABA) A receptor, delta 1.15 0.51 0.0 -1.02 0.91 0.0
5044_at GABRP gamma-aminobutyric acid (GABA) A receptor, pi 1.08 0.70 100.0 -1.07 0.81 100.0
206525_ at GABRR1 gamma-aminobutyric acid (GABA) receptor, rho 1 1.81 0.29 23.1 -1.27 0.53 15.2
208217_at GABRR2 gamma-aminobutyric acid (GABA) receptor, rho 2 -1.12 0.73 11.5 1.24 0.20 21.9
234410_at GABRR3 gamma-aminobutyric acid (GABA) receptor, rho 3 1.09 0.86 0.0 1.41 0.26 1.0
205890_s_at GABBR1 gamma-aminobutyric acid (GABA) B receptor, 1 -1.45 0.31 94.2 -1.75 1.79 ×
10-4
98.1
209990_s_at GABBR2 gamma-aminobutyric acid (GABA) B receptor, 2 -1.09 0.86 15.4 -1.33 0.42 7.6
Transport
205152_at GAT-1 solute carrier family 6 (neurotransmitter transporter,
GABA), member 1
-1.37 0.46 26.9 -1.70 0.14 44.7
237058_x_at GAT-2 solute carrier family 6 (neurotransmitter transporter,
GABA), member 13
-1.35 0.30 100.0 -1.13 0.60 99.1
207048_at GAT-3 solute carrier family 6 (neurotransmitter transporter,
GABA), member 11
-1.09 0.86 1.9 1.14 0.69 1.0
206058_at BGT-1 solute carrier family 6 (neurotransmitter transporter,
betaine/GABA), member 12
-1.18 0.70 17.3 -1.04 0.90 8.6
240532_at VGAT solute carrier family 32 (GABA vesicular transporter),
member 1
1.03 0.95 0.0 -1.15 0.69 0.0
Metabolism
209460_at GABA-T 4-aminobutyrate aminotransferase -1.45 7.25 ×
10-2
100.0 -1.45 5.41 ×
10-3
100.0
203608_at ALDH5A1 aldehyde dehydrogenase 5 family, member A1 -1.18 0.31 100.0 -1.15 0.12 100.0
1Data was obtained using the Affymetrix HG-U133 Plus 2.0 microarray chip.
2Fold-change represents the ratio of average expression value in healthy smokers to average expression value in healthy nonsmokers. Positive fold-changes
represent genes up-regulated by smoking; negative fold-changes represent genes down-regulated by smoking.
3p value obtained using Benjamini-Hochberg correction to limit the false positive rate.
4P call represents the % of healthy nonsmoker and healthy smoker samples in which the Affymetrix detection call for that probe set was “P” or “Present,” i.e., the
gene was expressed in that sample.
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S1A, B), with some correlation of MUC5AC and GAD67
protein expression (panel C).
Discussion
Cigarette smoking is associated with mucus hypersecre-
tion by the airway epithelium [10-12]. While the control
of mucus secretion is complex, a role of the GABAergic
system has been suggested to mediate, in part, the
hypersecretion of mucus associated with asthma
[6-9,17]. In the context that cigarette smoking is also
associated with mucus hypersecretion, in the present
study we asked the question: Does smoking alter the
gene expression pattern of GABAergic system genes in
the respiratory epithelium? Assessment of our database
of airway epithelial gene expression generated by micro-
arrays showed that, while many of the GABAergic sys-
tem genes are expressed in the human large and small
airway epithelium, cigarette smoking is associated with
changes in gene expression only of GAD67, a gene
controlling the synthesis of GABA [2]. A striking
increase in gene expression levels of GAD67 was
observed in the large and small airway epithelium of
healthy smokers compared to healthy nonsmokers, a
finding confirmed at the mRNA level by TaqMan PCR;
and at the protein level qualitatively by immunohisto-
chemistry, and quantitatively by Western analysis. There
was a positive correlation between GAD67 gene expres-
sion and MUC5AC at the mRNA level in both small
and large airway epithelium, as well as by MUC5AC
staining, suggesting a link between mucus overproduc-
tion and GAD67 overexpression in association with
smoking.
GABAergic System
GABA is the major inhibitory neurotransmitter in the
mammalian central nervous system [2,3]. In the mam-
malian brain, GABA is synthesized primarily from gluta-
mate in a reaction that is catalyzed by 2 glutamic acid
Figure 2 GABAergic system gene expression in large and small airway epithelium. A. Microarray present call analysis of GABAergic system
genes in large airway epithelium. B. Microarray present call analysis of GABAergic system genes in small airway epithelium. For A and B, the
dashed line represents P call of 20%. C. RT-PCR assessment of GABAergic system gene expression in large and small airway epithelium. Human
brain RNA was used as a positive control. Shown are representative RT-PCR results of 1 large airway epithelium sample and 1 small airway
epithelium sample.
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decarboxylase enzymes, GAD65 and GAD67, coded by
different genes [1-3]. GABA is then loaded into synaptic
vesicles by a vesicular neurotransmitter transporter
(VGAT) and liberated from nerve terminals by calcium-
dependent exocytosis. Nonvesicular forms of GABA
secretion (e.g., by reverse transporter action) have also
been described and are likely important during develop-
ment [18]. After being released from presynaptic nerve
terminals, GABA exerts its physiological effects through
ionotropic GABA-A receptors and metabotropic GABA-
B receptors [19]. The GABAergic neurotransmission is
terminated by rapid uptake of the neurotransmitter
from the synaptic cleft into neurons and glial cells by
specific high-affinity GABA transporters [20]. There are
4 distinct genes encoding membrane GABA transpor-
ters, GAT-1, GAT-2, GAT-3, and BGT-1 [20]. Subse-
quently, GABA is metabolized by a transamination
reaction that is catalyzed by GABA transaminase
(GABA-T). Succinic semialdehyde dehydrogenase
(ALDH5A1), which helps entry of the GABA carbon
skeleton into the tricarboxylic acid cycle, is the final
enzyme of GABA catabolism [1]. GABAergic system
genes are present not only in the brain, but also in
other organs, including liver, kidney, pancreas, testis,
oviduct, adrenal, and lung [3,4].
GABAergic System in the Lung
In the lung, immunohistochemistry studies of the guinea
pig trachea has identified GABA in airway epithelium,
chondrocytes and connective tissue near smooth muscle
[21]. GAD65/67 mRNA has been detected in human
and mouse airway epithelium at the mRNA level by RT-
PCR and at the protein level by Western analysis and
immunohistochemistry [7,22]. GABA and GAD 65/67
are also expressed in mouse pulmonary neuroendocrine
cells [23]. Of the 19 GABA-A receptor subunits identi-
fied in the mammalian genome, subunits alpha1, pi and
delta have been detected in human airway epithelium by
Western analysis, subunits beta 2/beta 3 in mouse air-
way epithelium by immunohistochemistry, and alpha 2,
gamma 3, beta 1 and pi in rat airway epithelium by
immunohistochemistry [24]. Some GABA-A receptor
subunits have also been identified in alveolar epithelial
cells [25]. There are different expression patterns of
some of the GABA-A receptor subunits during rat lung
development [24]. Of the GABA-B receptors, both
GABBR1 and GABBR2 subunits mRNA have been
detected in human airway epithelium and both subunits
have been identified by Western analysis and immuno-
histochemistry in guinea pig trachea [22]. Using specific
agonists, GABA-B receptors coupling to G proteins in
general and its specific coupling to the G protein was
shown in a human airway epithelial cell line [22]. To
our knowledge, there has been no prior assessment of
expression of GABA transporters or of GABA catabo-
lism enzymes in the human airway epithelium.
In the present study, we categorized the expression of
GABAergic system genes into 4 groups based on their
GABA-related function: synthesis, receptor, transport
Figure 3 Microarray assessment of smoking-induced change in
GABAergic system gene expression in large and small airway
epithelium. A. Volcano plot of GABAergic system gene-related
probe sets in large airway epithelium. B. Volcano plot of GABAergic
system gene-related probe sets in small airway epithelium. For both
panels, the x-axis corresponds to the fold-change and the y-axis
corresponds to p value. Black dots represent significant differentially
expressed probe sets; open dots represent probe sets with no
significant difference between healthy smokers and healthy
nonsmokers. The changes in gene expression were considered
significant based on the criteria of fold-change >2, p < 0.01, with
Benjamini-Hochberg correction
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and metabolism. The analysis demonstrated a complete
GABAergic system exists in the human large and small
airway epithelium, although there are differences com-
pared to the central nervous system. Interestingly, in the
human airway epithelium there is no VGAT expression,
suggesting GABA is released from airway epithelial cells
in a vesicle independent fashion [18]. Consistent with
our data, high pressure liquid chromatography demon-
strated that GABA could be produced in the guinea pig
trachea epithelium [26], and a functional GABA
transporter has been demonstrated in cultured human
airway epithelial cells [27].
Modification of GAD67 Expression by Smoking
Recent studies suggest the GABAergic system may have
a role in oxidative stress protection in neuron-related
cells and airway mucus production [7,28,29]. Our data
demonstrate that, while many of the GABAergic system
genes are expressed in the human large and small air-
way epithelium, only GAD67 is modified by cigarette
Figure 4 GAD67 gene expression levels in large and small airway epithelium of healthy smokers compared to healthy nonsmokers.
A. Average normalized gene expression levels of GAD67, assessed using HG-U133 Plus 2.0 microarray in large airway epithelium of 21 healthy
nonsmokers and 31 healthy smokers. The ordinate shows the average normalized gene expression levels for GAD67. B. Average normalized gene
expression levels of GAD67, assessed using HG-U133 Plus 2.0 microarray in small airway epithelium of 47 healthy nonsmokers and 58 healthy
smokers. C. TaqMan confirmation of changes in GAD67 gene expression levels in large airways of 10 healthy nonsmokers and 12 healthy
smokers. D. TaqMan confirmation of changes in GAD67 gene expression levels in small airways of 10 healthy nonsmokers and 12 healthy
smokers. The ordinate shows average gene expression levels and error bars represent standard error.
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smoking, with a marked increase in gene expression
levels of GAD67 in the large and small airway epithe-
lium of healthy smokers compared with healthy non-
smokers, and with a positive correlation between
GAD67 and MUC5AC, the major airway mucus-related
gene [16]. Considering the important role of ion
channels in airway surface water balance [30,31], further
studies could be directed to explore the effect of
GABAergic system changes affected by smoking on the
liquid microenvironment of airway epithelium.
The mechanisms responsible for GAD67 gene expres-
sion up-regulation by cigarette smoking remain to be
elucidated. It is known that nicotine, by activating nico-
tinic acetylcholine receptors located on cortical or hip-
pocampal GABAergic interneurons, can up-regulate
GAD67 expression via an epigenetic mechanism [32].
Inhibitors of DNA methyltransferases and histone deac-
tylases induce GAD67 expression [33,34]. In contrast to
this observation, nicotine suppresses protein levels of
GAD isozymes (mainly GAD65) and GABA in pancrea-
tic ductal adenocarcinoma tissue [35]. Interestingly,
nuclear factor-kappa B activation through oxidative
stress can up-regulate GAD67 expression [36], and the
early growth response factor 1-related pathway also
mediates GAD67 up-regulation [37]. Glucocorticoid
hormones can modulate GAD expression by transcrip-
tional activation of the GAD67 promoter [38]. Finally,
GAD can also be regulated at the post-translational
level by protein phosphorylation, palmitoylation and
cleavage [39]. Together, these findings suggest that
cigarette smoking may have a complicated effect on
GAD activity.
GABAergic System and Mucus Overproduction
A variety of observations link the GABAergic system to
mucus overproduction. Studies by Xiang et al [7]
demonstrated that GABA promotes the proliferation of
airway epithelial cells, an effect that was suppressed by a
GABA-A receptor antagonist, whereas activation of
GABA-A receptors depolarized airway epithelial cells.
After exposure to GABA for 6 days, cultured human air-
way epithelium demonstrated more mucus staining.
Moreover, ovalbumin-induced airway goblet cell hyper-
plasia and mucus overproduction could be blocked with
a GABA-A receptor antagonist in vivo. Studies from the
same group also showed that IL-4Ra is required for
allergen-induced up-regulation of GABAergic system in
airway epithelium, which might have a role in goblet
cell metaplasia following acute house dust mite exposure
[40].
Fu et al [41] showed that incubation of rhesus maca-
que bronchial epithelial cells with nicotine for 48 hr sig-
nificantly increased mucin mRNA levels. Interestingly,
the effect of nicotine was blocked both by the nicotinic
antagonists and by the GABA-A receptor antagonists.
This suggests that the sequential activation of nicotinic
signaling followed by GABAergic signaling is necessary
for nicotine to stimulate bronchial epithelial mucus pro-
duction, and that nicotine-induced mucin overproduc-
tion is, in part, dependent on GABA-A receptor
Figure 5 Immunohistochemistry assessment of GAD67
expression in large airway epithelium in healthy nonsmokers
and healthy smokers, representing the broad range of up-
regulation of the GAD67 gene. Panels A, C, E, G, I, K, stained
with anti-GAD67 antibody. Panels B, D, F, H, J, L, stained with
mouse IgG control. A. Healthy nonsmoker, anti-GAD67; B. Healthy
nonsmoker, IgG; C. Healthy smoker, anti-GAD67; D. Healthy smoker,
IgG; E. Healthy nonsmoker, anti-GAD67; F. Healthy nonsmoker, IgG;
G. Healthy smoker, anti-GAD67; H. Healthy smoker, IgG; I. Healthy
smoker, anti-GAD67; J. Healthy smoker, IgG; K. Healthy smoker, anti-
GAD67; and L. Healthy smoker, IgG l. Bar = 10 μm.
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signaling in bronchial epithelial cells. Ly6/neurotoxin 1
(Lynx1), the founding member of a family of mamma-
lian prototoxins, modulates nicotinic acetylcholine
receptors in vitro by altering agonist sensitivity and
desensitization kinetics [42]. Results from Lynx1 knock-
down experiments suggested that Lynx1 acts as a nega-
tive modulator of nicotine-mediated activation of
GABAergic signaling [43]. Interestingly, when BALB/c
mice were exposed to secondhand smoke, there was an
excellent correlation between increased GABA-A recep-
tor staining and lung mucous cell metaplasia [44].
Based on the observations in the present study, there
may be a therapeutic advantage to use GAD67 as a
pharmacologic target for smoking-related disorders in
the lung. However, while mucus overproduction is
commonly associated with smoking and many COPD
patients have mucus production, there is variability in
the extent of mucus production among smokers and
smoking-related disorders [45], any therapy focused on
mucus overproduction would have to be tailored to the
individual.
Conclusions
There is a complete GABAergic system in human large
and small airway epithelium. Marked up-regulation of
GAD67 by cigarette smoking is associated with
MUC5AC overexpression. In the context of these obser-
vations, the GABAergic system is a promising pharma-
cological target for inhibiting airway mucus
overproduction.
Figure 6 Western analysis of GAD67 protein expression in small airway epithelium of healthy nonsmokers and healthy smokers.
A. Upper panel - GAD67 protein expression in nonsmokers (lanes 1-6), smokers (lanes 7-12) and positive control (lane 13). Lower panel - same
gel probed with anti b-actin antibody; 20 μg protein loaded per well. B. Ratio of GAD67 to b-actin. The ratio of GAD67 to b-actin is represented
on the ordinate for smoker and nonsmoker bands. Error bars represent the standard error. Note in panel A, the variability in relative up-
regulation of GAD67 in the smokers, similar to that observed at the mRNA level and with immunohistochemistry.
Wang et al. Respiratory Research 2010, 11:150
http://respiratory-research.com/content/11/1/150
Page 12 of 15
Figure 7 Association of GAD67 gene expression and MUC5AC expression. A, B. Correlation between GAD67 and MUC5AC gene expression
in the large and small airway epithelium (Pearson’s correlation). A. Average normalized gene expression levels of GAD67 vs MUC5AC gene
expression in the large airway epithelium. B. Average normalized gene expression levels of GAD67 vs MUC5AC gene expression in the small
airway epithelium. C-F. Representative MUC5AC staining on large and small airway epithelial cells from healthy smokers with high GAD67 and
high MUC5AC gene expression or with low GAD67 and low MUC5AC gene expression at mRNA level. “High” or “low” gene expression is defined
in Methods and based on microarray data. C. MUC5AC staining on large airway brushed cells of healthy smokers with high GAD67 and high
MUC5AC gene expression (marked as red solid circles in panel A). D. MUC5AC staining on small airway brushed cells of healthy smokers with
high GAD67 and high MUC5AC gene expression (marked as red solid circles in panel B). E. MUC5AC staining on large airway brushed cells of
healthy smokers with low GAD67 and low MUC5AC gene expression (marked as blue solid circles in panel A). F. MUC5AC staining on small
airway brushed cells of healthy smokers with low GAD67 and low MUC5AC gene expression (marked as blue solid circles in panel B). In all
panels, IgG controls showed no MUC5AC staining (not shown). Bar = 10 μm.
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